Roche Applied Science Launches the E-Plate Insert for Analysis of Cell-Cell Interactions using the xCELLigence System
2 Pages
English

Roche Applied Science Launches the E-Plate Insert for Analysis of Cell-Cell Interactions using the xCELLigence System

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

Roche Applied Science Launches the E-Plate Insert for Analysis of Cell-Cell Interactions using the xCELLigence System PR Newswire PENZBERG, Germany, June 13, 2012 PENZBERG, Germany, June 13, 2012 /PRNewswire/ -- The co-cultivation of two different cell types is an important way to investigate cell-cell interactions and communication.

Subjects

Informations

Published by
Reads 10
Language English
Roche Applied Science Launches the E-Plate
Insert for Analysis of Cell-Cell Interactions
using the xCELLigence System
PR Newswire
PENZBERG, Germany, June 13, 2012
PENZBERG,
Germany
,
June 13, 2012
/PRNewswire/ --
The co-cultivation of two different cell types is an important way to investigate
cell-cell interactions and communication.
Co-cultivation can be used in a wide variety of applications, including cell
signalling and toxicology testing. A key goal in drug discovery is to identify how
to most effectively monitor cell-cell interactions when cells show pathology.
Roche Applied Science is now providing the new E-Plate Insert 16 and E-Plate
Insert 96, permitting continual impedance-based monitoring of indirect cell-cell
interactions/communication using xCELLigence Instruments.
In a recent study at the INRS-Institut Armand-Frappier (
Laval, Quebec, Canada
)
the E-Plate Insert had been used to test the behaviour of BeWo human
placental choriocarcinoma cells in co-culture with H295R human adrenocortical
carcinoma cells. "Using the E-Plate Insert in our co-culture experiments
requires fewer manipulations and allows us to perform several experiments
simultaneously - hormone measurements, signalling pathway analysis, real-
time monitoring of biochemical and morphological differentiation of the cells,"
summarized Prof. Thomas Sanderson and Prof. Cathy Vaillancourt, who are co-
investigators on this project and co-supervisors of Andrée-Anne Hudon
Thibeault, the Masters student who realised the study. The Canadian group
plans to use the unique abilities of the co-culture-compatible E-Plate Insert and
xCELLigence cell response monitoring technology, to determine the effect of
co-culture on primary villous trophoblast homeostasis (polarization,
differentiation/syncytialization, fusion, apoptosis) and on H295R cells
(proliferation, viability, apoptosis) as well as expression and activity levels of key
placental and fetal adrenal steroidogenic enzymes.
The membrane-containing E-Plate Inserts enable sensitive, reproducible
measurement of indirect cell-to-cell interactions in real-time, and in a label-free
environment using the xCELLigence Instruments (RTCA DP, SP, and MP
Analyzers). Combined with microscopy-compatible E-Plates VIEW, E-Plate
Inserts 16 and 96 are available for low to high throughput applications.
Impedance-based measurements are particularly advantageous when co-
culturing cells for pinpointing when and how cells respond to each other, thus
identifying the best time points for further experiments.
About Roche
Headquartered in
Basel, Switzerland
, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world's largest biotech company with truly differentiated medicines in
oncology, virology, inflammation, metabolism and central nervous system
(CNS). Roche is also the world leader in in-vitro diagnostics, tissue-based cancer
diagnostics and a pioneer in diabetes management. Roche's personalized
healthcare strategy aims at providing medicines and diagnostic tools that
enable tangible improvements in the health, quality of life and survival of
patients. In 2011, Roche had over 80,000 employees worldwide and invested
over
8 billion Swiss francs
in R&D. The Group posted sales of
42.5 billion Swiss
francs
. Genentech,
United States
, is a wholly owned member of the Roche
Group. Roche has a majority stake in Chugai Pharmaceutical,
Japan
. For more
information: http://www.roche.com.
XCELLIGENCE is a trademark of Roche.
E-PLATE and ACEA BIOSCIENCES are registered trademarks of ACEA
Biosciences, Inc. in the US.
For life science research only. Not for use in diagnostic procedures
For further information please contact:
Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: burkhard.ziebolz@roche.com